PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 9, 2007New England Journal of Medicine1,907 citations

Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases

View Full Paper
SGSuzanne M. GarlandMHMauricio Hernández‐ÁvilaCWCosette M. Wheeler

Key Points

  • The aim is to evaluate the efficacy of a quadrivalent vaccine in reducing HPV-associated anogenital diseases among young women.
  • Conducted a randomized trial, detailed in ClinicalTrials.gov NCT00092521.
  • Focus on incidence rates of HPV-related anogenital diseases.
  • Significant reduction in the incidence of HPV-associated anogenital diseases among vaccinated participants.

Abstract

The quadrivalent vaccine significantly reduced the incidence of HPV-associated anogenital diseases in young women. (ClinicalTrials.gov number, NCT00092521 ClinicalTrials.gov.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Garland et al. (2007) studied this question.

synapsesocial.com/papers/69d776beaa68b335b4f3199ehttps://doi.org/10.1056/nejmoa061760
Ask AI
Helpful
Bookmark
Share
View Full Paper